Antibody Drug Conjugates Market - By Product Type (Adcetris, Perjeta, Kadcyla), Technology (Cleavable Linker, Non-cleavable, Linkerless) Application (Blood Cancer, Breast Cancer), Target Type (CD30 Antibodies, HER2 Antibodies) & Global Forecast 2024 - 2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAntibody Drug Conjugates Market - By Product Type (Adcetris, Perjeta, Kadcyla), Technology (Cleavable Linker, Non-cleavable, Linkerless) Application (Blood Cancer, Breast Cancer), Target Type (CD30 Antibodies, HER2 Antibodies) & Global Forecast 2024 - 2032
Antibody Drug Conjugates Market Size
Antibody Drug Conjugates Market size accounted for USD 7.7 billion in 2023 and is estimated to grow at CAGR of 14.8% to reach USD 26.6 billion by 2032. Increasing incidence of cancer globally coupled with growing demand for targeted therapies is expected to boost the market value.
The GLOBOCAN study carried out by the International Agency for Research on Cancer stated that in 2020, an expected of 19.3 million new cases of cancer and around 10.0 million deaths due to cancer were reported across the world. Also, antibody drug conjugates (ADCs) provide targeted delivery mechanism that allows specific recognition and binding to cancer cells, resulting in enhanced efficacy and reduced systemic toxicity compared to traditional chemotherapy.
| Report Attribute | Details |
|---|---|
| Base Year | 2023 |
| Antibody Drug Conjugates Market Size in 2023 | USD 7.7 Billion |
| Forecast Period | 2024 to 2032 |
| Forecast Period 2024 to 2032 CAGR | 14.8% |
| 2032 Value Projection | USD 26.6 Billion |
| Historical Data for | 2018 to 2023 |
| No. of Pages | 180 |
| Tables, Charts & Figures | 276 |
| Segments covered | Product Type, Technology, Application, Target Type and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
Antibody drug conjugates (ADCs) are a class of targeted therapeutics designed to selectively deliver potent cytotoxic drugs to cancer cells. They are composed of three main components that include a monoclonal antibody, cytotoxic payload and a linker molecule. ADCs deliver the cytotoxic payload directly to the cancer cells while minimizing damage to healthy cells, thereby improving efficacy and reducing systemic toxicity associated with traditional chemotherapy. The specific targeting and payload delivery mechanisms of ADCs make them a promising approach in the field of cancer treatment.
COVID-19 Impact
The COVID-19 pandemic has turned millions of lives upside down around the world. Its severity and the risk of death have made scientists race to find ways to fight it. To this end, the U.S. Food and Drug Administration (FDA) and other countries have given emergency approval to several antibodies and antibody drug combinations for use on COVID-19 patients with mild or moderate cases. For example, Eli Lilly and Co. got the go-ahead to use its antibody combination drug in India to treat mild to moderate COVID-19. And GlaxoSmithKline's antibody treatment also got emergency approval from the U.S. FDA.
Antibody Drug Conjugates Market Trends
Cancer is on the rise around the world, and we desperately need new treatments that work better and cause fewer side effects. That's where antibody drug conjugates (ADCs) come in. ADCs are a unique type of cancer therapy that combine the precision of antibodies with the power of chemotherapy drugs. Antibodies are like smart missiles that can target and bind to specific proteins on cancer cells. Then, the chemotherapy drug attached to the antibody is released, killing the cancer cell while leaving healthy cells alone. ADCs also have the potential to overcome one of the biggest challenges in cancer treatmentdrug resistance. Some cancer cells develop the ability to pump out or block the drugs we use to treat them. ADCs can get past these resistance mechanisms, making them more effective against difficult-to-treat cancers. Plus, ADCs can be used in combination with other therapies to create personalized treatment plans that are tailored to each patient's individual needs. This approach can lead to better outcomes and a higher quality of life for people with cancer.
Antibody Drug Conjugates Market Analysis
Antibody drug conjugates are a type of cancer treatment that combines antibodies with chemotherapy drugs. They come in different varieties, including Adcetris, Perjeta, Kadcyla, and others. Kadcyla is a standout player in the antibody drug conjugate market. It grabbed 32.5% of the market in 2022. That's because Kadcyla is specifically designed to go after cancer cells that have too much of a protein called HER2. It delivers a powerful chemotherapy agent right to the tumor, like a targeted missile. This smart approach means Kadcyla can be more effective against cancer while causing fewer side effects for patients. It's like a sharpshooter that takes out the bad guys without harming the innocent bystanders. Thanks to these advantages, Kadcyla has become a popular choice for treating breast cancer that's HER2-positive. It's been given the green light in many countries, helping patients fight back against this tough disease.
Based on technology, the antibody drug conjugates market is segmented into cleavable linker, non-cleavable linker and linkerless. The cleavable linker is expected to register over USD 14.3 billion by 2032. Cleavable linker technology is one of the significant advancements in antibody drug conjugates that enables to release the cytotoxic payload specifically within cancer cells, thereby enhancing treatment efficacy. Cleavable linker technology allows for precise delivery of potent drugs to the target site, ensuring that the cytotoxic payload is released in a controlled manner, thereby maximizing its impact on cancer cells while sparing healthy tissues.
Imagine you're battling cancer. Doctors have a new weaponantibody drug conjugates (ADCs). These are like tiny soldiers that can seek out and destroy cancer cells. ADCs are used to treat many types of cancer, including breast, blood, and lung. The breast cancer squad is particularly impressive. It's predicted to grow by a whopping 15.3% by 2032! Here's how ADCs workthey use smart molecules called monoclonal antibodies to spot and latch onto proteins like HER2, which are common on cancer cells. Once attached, the ADC delivers a powerful punch of cytotoxic drugs straight to the cancer, like a guided missile. This targeted approach is a game-changer in breast cancer treatment. Studies show that ADCs boost the number of patients who respond to treatment, help them live longer without their cancer coming back, and improve their overall well-being.
Antibody drug conjugates (ADCs) are a game-changer in cancer treatment, combining the power of antibody-targeted delivery with potent drugs. The market for ADCs is vast, with different types of targets like HER2 and CD30. In 2022, HER2 antibodies alone were a huge market, generating a significant revenue of 3.3 billion dollars. Why? Because many cancers like breast and stomach cancers have too much HER2 protein, which ADCs can target precisely. ADCs armed with HER2 antibodies help deliver powerful drugs right to cancer cells that have too much HER2. They're like precision missiles, delivering a targeted dose of chemotherapy. This makes them a vital part of cancer treatments, helping to attack specific cells and spare healthy tissue. Plus, there are a lot of clinical trials happening right now for breast cancer and other solid tumors, which means ADCs have the potential to become even more effective in the future.
North America antibody drug conjugates market accounted for over 49.5% business share in 2022. The increasing prevalence of cancer and growing demand for targeted therapies is expected to boost the market gains in the North America region. Also, advanced healthcare infrastructure, presence of key players and strong R&D facilities have contributed to the significant adoption and commercial success of ADCs, thereby augmenting the market progression in the North America region.
Antibody Drug Conjugates Market Share
Major market players operating in the antibody drug conjugates market include
- Seagen Inc.
- Pfizer Inc.
- F.Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
Antibody Drug Conjugates Industry News
- In April 2023, Innate Pharma have signed agreement with Takeda Pharmaceutical Company Ltd to enable research and development of antibody drug conjugates (ADCs), primarily focusing on coeliac disease. This strategy is expected to help Takeda secure exclusive rights globally to use a set of selected Innate antibodies to create, manufacture and commercialize the ADCs.
- In March 2023, Pfizer Inc and Seagen Inc have entered into a definitive merger agreement under which Pfizer will acquire Seagen. This acquisition is aimed at pioneering expertise in antibody-drug conjugates (ADCs) that strongly complement Pfizer’s Oncology portfolio. This acquisition is expected to help the company to gain strong foothold in antibody-drug conjugates (ADCs) market and drive revenue growth.
The antibody drug conjugates market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Product Type
- Adcetris
- Perjeta
- Kadcyla
- Other product type
Technology
- Cleavable Linker
- Non-cleavable Linker
- Linkerless
Application
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Other applications
Target Type
- CD30 Antibodies
- HER2 Antibodies
- Other target types
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy